Occupational Therapists in Sandown, NH Accepting Medicare
5 Occupational Therapists found. Showing 1 - 5
 Sandra Bishop Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 92 Wells Village Rd, Sandown, NH 03873 Phone: 603-247-4350 |
Mrs. Brittany Lynn Grant Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 23 Stagecoach Dr, Sandown, NH 03873 Phone: 603-801-9792 |
 Mr. Joseph Boucher, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5 Birch Dr, Sandown, NH 03873 Phone: 603-887-1023 |
 Functional Home Adaptations Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 92 Wells Village Rd, Sandown, NH 03873 Phone: 603-247-4350 |
Kendra Wakeen, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 56 Compromise Ln, Sandown, NH 03873 Phone: 603-377-6019 |
News Archive
Tell tale neurologic soft signs for schizophrenia and bipolar disorder
Neurologic soft signs can differentiate schizophrenia from major depression but not bipolar disorder, study findings indicate.
Study explores prevalence of myocardial scars in middle-aged and older population
In a multiethnic, middle-aged and older study population, the prevalence of myocardial scars (evidence of a heart attack) was nearly 8 percent, of which nearly 80 percent were unrecognized by electrocardiography or clinical evaluation, according to a study in the November 10 issue of JAMA.
Our thirst for novelty begins in the eye itself
Researchers at Harvard University have found evidence that the retina actively seeks novel features in the visual environment, dynamically adjusting its processing in order to seek the unusual while ignoring the commonplace. The scientists report in this week's issue of the journal Nature on their finding that this principle of novelty-detection operates in many visual environments.
FDA approves brand name VELETRI for Actelion's epoprostenol for injection therapy
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
› Verified 3 days ago